AstraZeneca’s Challenge to Price Negotiation Fails in Federal District Court
FDA Law Blog
MARCH 5, 2024
To the extent that AstraZeneca alleged that CMS would cause it this type of harm in 2027, the court found that allegation to be too speculative. According to the court, AstraZeneca’s “desire” or even “expectation” to sell its drugs to the Government at the higher prices it once enjoyed does not create a protected property interest.”
64 
Let's personalize your content